CXCR5 and cancer: Notably, upon combination therapy, ASPH-MYC and downstream PD-L1/PD-1 signals were blocked; CTLs secreted CXCL13 could bind to CXCR5 on cancer cells and produce cytotoxicity against them efficiently (Supplemental Fig. S5B; Fig. 6).